Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK Celebrates 2024 IMPACT Award Winners
Investments now totaling nearly $16.5M to improve health in the Triangle (North Carolina) and Greater Philadelphia regions.
Download (PDF, 163.6KB) -
GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S.
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines.
Download (PDF, 128.1KB) -
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Download (PDF, 271.2KB) -
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Studies from OPERA and Trio cohorts provide further real-world evidence.
Download (PDF, 271.8KB) -
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials
Download (PDF, 133.0KB) -
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 314.0KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK will continue to provide data on longer-term follow-up to help recommending bodies determine future revaccination schedules
Download (PDF, 274.3KB) -
GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
GSK announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the safety of AREXVY and SHINGRIX.
Download (PDF, 189.4KB) -
Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
GSK confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell and Annette Hughes.
Download (PDF, 138.1KB) -
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
GSK’s THRIVE@50+ campaign with Brooke Shields encourages people aged 50 and over to discuss shingles risk and vaccination with their doctor.
Download (PDF, 207.8KB) -
Statement: Zantac (ranitidine) litigation – Dixon case
GSK confirmed it has reached a settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court.
Download (PDF, 112.0KB) -
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announced results of MATINEE, evaluating Nucala, a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD.
Download (PDF, 429.6KB) -
Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Download (PDF, 123.0KB) -
Statement: Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Download (PDF, 124.1KB) -
Statement: Zantac litigation – Joiner case
Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
Download (PDF, 126.9KB) -
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
Download (PDF, 318.6KB) -
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
Download (PDF, 130.7KB) -
Statement: Zantac (ranitidine) litigation – Kimbrow case
GSK has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court.
Download (PDF, 110.4KB)
